Advanced search
Publication Cover
Renal Failure Volume 42, 2020 - Issue 1
Submit an article Journal homepage
1,561
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Successful treatment of anti-EPO antibody associated refractory anemia with hypoxia-inducible factor prolyl hydroxylase inhibitor

Huifang ZhangDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Zineng HuangDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Liyu HeDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Fang YuanDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Lin SunDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Fuyou LiuDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
&
Li XiaoDepartment of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 860-864 | Received 14 Jun 2020, Accepted 23 Jul 2020, Published online: 19 Aug 2020

References

  • Lankhorst CE, Wish JB. Anemia in renal disease: diagnosis and management. Blood Rev. 2010;24(1):39–47.
  • Shin SK, Pack SP, Oh JG, et al. Anti-erythropoietin and anti-thrombopoietin antibodies induced after administration of recombinant human erythropoietin. Int Immunopharmacol. 2011;11(12):2237–2241.
  • Khalil SK, Amer HA, El Behairy AM, et al. Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: molecular and biochemical studies. J Adv Res. 2016;7(3):348–358.
  • Kim IY, Kim JH, Kim MJ, et al. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int Urol Nephrol. 2018;50(12):2255–2260.
  • Bamgbola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol. 2009;24(3):571–579.
  • Pereira R, Costa E, Gonçalves M, et al. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationship with resistance to recombinant human erythropoietin and to the hemodialysis procedure. Hemodial Int. 2010;14(3):295–301.
  • Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410.
  • Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157–168.
  • Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381(11):1001–1010.
  • Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.